Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477687 | 0.86 | CNR2 (0.63) | HRH3MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4465612 | 0.86 | HRH3 (0.59) | HRH3MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4488918 | 0.82 | HRH3 (0.67) | HRH3MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| 4-(4-Chlorobenzyl)Morpholine SCHEMBL4103722 | 0.81 | HRH3 (0.74) | HRH3MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5618352 | 0.79 | SMN1; SMN2 (0.71) | HRH3KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL26124351 | 0.79 | ALDH1A1 (0.64) | HRH3SMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL4477174 | 0.77 | CNR2 (0.80) | CNR2 | |
| SCHEMBL15467001 | 0.77 | HRH3 (0.87) | HRH3MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4477181 | 0.77 | CNR2 (0.80) | CNR2 | |
| SCHEMBL4472255 | 0.76 | KDM4E (0.60) | HRH3SMN1; SMN2ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1966132-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | HRH3 283/4885MAPT 3519/4885KMT2A 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.